Company Overview

Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, filtration, purification, and fluid management services; single-use and reusable hollow-fiber membrane devices, as well as presterilized assemblies for cell and gene therapy applications; and cell harvesting and various other solutions for intensified bioprocesses. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production. It serves manufacturers of pharmaceuticals, foods, and chemicals, as well as research and development laboratories. The company was founded in 1870 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.

  • Name

    Sartorius Stedim Biotech S.A.

  • CEO

    Dr. Rene Faber

  • Website

    www.sartorius.com

  • Sector

    Life Sciences Tools and Services

  • Year Founded

    1978

Profile

  • Market Cap

    €17.39B

  • EV

    €19.89B

  • Shares Out

    97.31M

  • Revenue

    €2,746.9M

  • Employees

    10,382

Margins

  • Gross

    43.16%

  • EBITDA

    23.73%

  • Operating

    15.18%

  • Pre-Tax

    8.61%

  • Net

    6.17%

  • FCF

    11.1%

Returns (5Yr Avg)

  • ROA

    12.85%

  • ROTA

    37.58%

  • ROE

    24.82%

  • ROCE

    25.23%

  • ROIC

    16.91%

Valuation (TTM)

  • P/E

  • P/B

  • EV/Sales

  • EV/EBITDA

  • P/FCF

  • EV/Gross Profit

Valuation (NTM)

  • Price Target

    €211.79

  • P/E

  • PEG

  • EV/Sales

  • EV/EBITDA

  • P/FCF

Financial Health

  • Cash

    €454.1M

  • Net Debt

    €2,464.9M

  • Debt/Equity

    0.74

  • EBIT/Interest

    2.47

Growth (CAGR)

  • Rev 3Yr

    4.71%

  • Rev 5Yr

    15.51%

  • Rev 10Yr

    16.05%

  • Dil EPS 3Yr

    -29.3%

  • Dil EPS 5Yr

    -6.94%

  • Dil EPS 10Yr

    9.49%

  • Rev Fwd 2Yr

    4.52%

  • EBITDA Fwd 2Yr

    7.94%

  • EPS Fwd 2Yr

    4.95%

  • EPS LT Growth Est

    21.15%

Dividends

  • Yield

  • Payout

    38.36%

  • DPS

    €0.69

  • DPS Growth 3Yr

    0.49%

  • DPS Growth 5Yr

    3.9%

  • DPS Growth 10Yr

    13.18%

  • DPS Growth Fwd 2Yr

    3.37%

ENXTPA:DIM